International Society

Legendary Texas Trial Lawyer Richard A. 'Dick' Sayles Announces New Venture

Retrieved on: 
Friday, June 2, 2023
Benchmark, Barrister, Reuters, National Board of Trial Advocacy, The National Law Journal, International Society of Barristers, Lawyer, American Board of Commissioners for Foreign Missions, Bradley, American College of Trial Lawyers, Dallas Bar Association, Love, International Society, International Academy, Steven Naifeh, American College, Practice of law

DALLAS, June 2, 2023 /PRNewswire/ -- After more than 40 years of trying cases throughout Texas and across the country, trial lawyer Richard A. "Dick" Sayles is just getting started. His new venture, The Sayles Law Firm, opens for business on June 2.

Key Points: 
  • DALLAS, June 2, 2023 /PRNewswire/ -- After more than 40 years of trying cases throughout Texas and across the country, trial lawyer Richard A.
  • "I love the law and am passionate about advocating for clients in important and interesting cases," says Mr. Sayles.
  • Dick Sayles is one of the most successful lawyers in Texas, and Sayles Werbner was once named among the top five "winningest" trial law firms in the country by The National Law Journal.
  • He earned National Board Certification as a trial lawyer Advocate by the National Board of Trial Advocacy; among the highest and most difficult honors an attorney can achieve.

ISHLT 2023 Annual Meeting Awards Showcase Advances in Treatment of Advanced Heart and Lung Disease

Retrieved on: 
Friday, June 2, 2023
Abstract, Society, University, UT, Lymphoproliferative disorders, Lung transplantation, Cancer, University of New South Wales, Research, Transplant, GA, University of Utah, Philip, Asian Americans Advancing Justice Southern California, Journal, Patient, Microcirculation, LVEDD, Heart failure, Stanford University School of Medicine, Heart transplantation, LVAD, Great Ormond Street Hospital, MCS, International Society, Dentistry, Medical device, Nursing, Birth control, Heart, Stanford University

Chicago, IL, June 02, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation 43rd Annual Meeting & Scientific Sessions included more than 1,250 presentations on improving outcomes for patients with advanced heart and lung disease from investigators from around the world.

Key Points: 
  • Chicago, IL, June 02, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation 43rd Annual Meeting & Scientific Sessions included more than 1,250 presentations on improving outcomes for patients with advanced heart and lung disease from investigators from around the world.
  • All conference abstracts are available in a special supplement to the Journal of Heart and Lung Transplantation’s April 2023 issue.
  • The team evaluated donor characteristics associated with heart acceptance in the USA and applied modern analytic methods to improve the prediction of heart acceptance.
  • Purpose: Heart transplant remains the gold standard treatment for patients with advanced heart failure.

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

Retrieved on: 
Thursday, June 1, 2023
ASC, CRISPR, CELU, Placenta, Gene, Thrombogenicity, Diabetic foot ulcer, ISCT, Immunomodulation, Instituto de Biologia Molecular e Celular, Cell, Multiple sclerosis, FSHD, Stem cell, Microsoft Exchange Server, Thrombosis, MSC, Facioscapulohumeral muscular dystrophy, TF, Data, Blood, Abdominal ultrasonography, Phenotype, International Society, Safety, Pharmaceutical industry, Vaccine, Cytotherapy

FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today the online publication of preclinical data in Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT).

Key Points: 
  • The paper, “Characterization of CRISPR/Cas9-edited human placental allogenic stromal cells with low tissue factor expression and reduced thrombotic effects,” (Huang, et al.
  • )1 examined methods to reduce the tissue factor expressed by allogeneic stromal cells (ASCs), which has been regarded as a safety concern in clinical applications as it may trigger thrombosis when ASCs are administered intravenously.
  • Thrombogenic risk has been identified in association with intravenous administration of mesenchymal stem cells (MSCs), both allogeneic and autologous.
  • These cells express procoagulant activity linked to the expression of tissue factor that, when in contact with blood, initiates coagulation.

Istation celebrates 25 years of educational excellence

Retrieved on: 
Thursday, June 1, 2023
Educational technology, Learning, School, Student, ISTE, History, International Society, Reading, Tutoring, Management, Education, ISTAT

Dallas, TX, June 01, 2023 (GLOBE NEWSWIRE) -- Istation, a leader in educational technology, is proud to celebrate its 25th anniversary this year.

Key Points: 
  • Dallas, TX, June 01, 2023 (GLOBE NEWSWIRE) -- Istation, a leader in educational technology, is proud to celebrate its 25th anniversary this year.
  • For more than two decades, educators have turned to Istation as an all-in-one solution for online assessment, instruction, and personalized learning.
  • With more than 17 million students served, Istation has become a leading provider of engaging, game-like learning in reading, math, and Spanish literacy.
  • For 25 years Istation has been pioneering computer-adaptive assessments with instant feedback to help educators make data-driven decisions.

T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
MYT, ISCT, MAGE-A1, Neoplasm, Clinical trial, Cancer, TCR, Patient, SAN, Superior, Annual general meeting, Cell, Mouse, Therapy, International Society, Vaccine

“These preclinical findings further highlight that TCRs derived from T-knife’s unique MyT™ platform provide differentiated results when compared to TCRs isolated from human donors,” said Elisa Kieback, Ph.D., Chief Technology Officer of T-knife.

Key Points: 
  • “These preclinical findings further highlight that TCRs derived from T-knife’s unique MyT™ platform provide differentiated results when compared to TCRs isolated from human donors,” said Elisa Kieback, Ph.D., Chief Technology Officer of T-knife.
  • “Specifically, leveraging our MyT platform, we isolated TK 8001, a naturally optimized high-affinity TCR specific for the cancer testis antigen MAGE-A1.
  • TK-8001, has repeatedly demonstrated superior in vitro anti-tumor activity against cancer cell lines derived from a wide range of tumors and superior in vivo anti-tumor activity in a very challenging syngeneic tumor mouse model.”
    MAGE-A1-specific TCRs were isolated from MyT platform mice immunized with the MAGE-A1 epitope.
  • Human donor-derived TCRs reactive to the same epitope were synthesized based on publicly available sequences, including a clinical-stage TCR.

Orthofix Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc With Other Clinical and Scientific Abstracts at the ISASS Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
FDA, Surgery, Medical Devices, Health, Clinical Trials, Abstract, Risk, Arm, Hip, PEMF, Radiculopathy, Diabetes, Osteoporosis, Trinity, Convention, VAS, Multimedia, Research, Neck, SF-36, National Primate Research Exhibition Hall, Osteolysis, IDE, Nonunion, NDI, International Society, Birth control, Medical device, Patient

View the full release here: https://www.businesswire.com/news/home/20230601005376/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230601005376/en/
    Illustration of the Orthofix M6-C artificial cervical disc.
  • (Graphic: Business Wire)
    “We are pleased to support a wide range of abstracts and clinical data during the annual ISASS meeting, including the first presentation of the seven-year data from the M6-C artificial cervical disc U.S. IDE study,” said Kevin Kenny, President of Global Spine.
  • “M6-C Artificial Cervical Disc: Seven-Year Outcomes for Single-Level Total Disc Replacement with a Novel Viscoelastic Artificial Cervical Disc” – abstract presentation by Dr. Todd Lanman.
  • This abstract is the first public presentation of specific seven-year clinical results associated with the use of the M6-C artificial cervical disc for the treatment of single-level symptomatic cervical radiculopathy.

BioCentriq® Launches LEAP™ Advanced Therapy Platform with Proven Assets and Expertise that Help Early-Stage BioTech Companies Reach Patients in Record Time

Retrieved on: 
Thursday, June 1, 2023
Pressure, CDMO, International Society, ISCT, Cell, Pharmaceutical industry

NEWARK, N.J., June 1, 2023 /PRNewswire/ -- BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy launched their new LEAP™ Advanced Therapy Platform today at the 29th International Society for Cell & Gene Therapy (ISCT) annual event.

Key Points: 
  • NEWARK, N.J., June 1, 2023 /PRNewswire/ -- BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy launched their new LEAP™ Advanced Therapy Platform today at the 29th International Society for Cell & Gene Therapy (ISCT) annual event.
  • "In the current economic environment, biotech companies with promising candidates are under greater pressure than ever to demonstrate results quickly," said Haro Hartounian, Ph.D. and CEO and Founder of BioCentriq.
  • "The LEAP™ platform is designed to help early-stage biotech companies prioritize speed in a very calculated and conscientious manner without compromising quality or introducing unnecessary risks."
  • The LEAP™ advanced therapy platform utilizes pre-existing assets and expertise to reduce process development and scale-up timelines by up to 75%.

Bluum Showcases Cutting-Edge Educational Technology Solutions at ISTE 2023

Retrieved on: 
Wednesday, May 31, 2023
Educational technology, Learning, International Society for Technology in Education, Student, International Society, ISTE, Safety, Nursing, Tourism, Education, PHOENIX

PHOENIX, May 31, 2023 /PRNewswire/ -- Booth 2750 becomes a hub of excitement and inspiration as Bluum takes the spotlight at the prestigious International Society for Technology in Education (ISTE) conference in 2023.

Key Points: 
  • Company aims to assist districts in planning, funding, product selection and deployment of educational solutions focusing on enhancing student engagement and safety
    PHOENIX, May 31, 2023 /PRNewswire/ -- Booth 2750 becomes a hub of excitement and inspiration as Bluum takes the spotlight at the prestigious International Society for Technology in Education (ISTE) conference in 2023.
  • Bluum invites all educational leaders to book a free consultation with their team of strategic advisors and product experts by visiting: https://outlook.office365.com/owa/calendar/[email protected]...
    Together, they can develop a customized plan for technology solutions that meet the specific needs of each district.
  • With a focus on enhancing student engagement and safety, Bluum is at the forefront of educational technology solutions.
  • By collaborating with Bluum, educators invest in practical solutions that improve learning outcomes, streamline operations, and stay ahead of the curve in today's rapidly evolving educational landscape.

Leading child mental health organisations call for global action against infant, child and adolescent trauma

Retrieved on: 
Thursday, June 1, 2023
Learning, SCAP, American Academy of Child and Adolescent Psychiatry, Society, Child and adolescent psychiatry, International Association for Child and Adolescent Psychiatry and Allied Professions, Disability, AACAP, Supervised visitation, Mental health, Institute of Psychiatry, Psychology and Neuroscience, International Association, American Academy, Adverse childhood experiences, King's College London, Academy of Medicine, DSM-IV codes, Bentham Science Publishers, National Children's Mental Health Awareness Week, ASCAP, Royal Australian and New Zealand College of Psychiatrists, ACeS, Journal of Indian Association for Child and Adolescent Mental Health, International Society, Growth, Trauma, IACAPAP, Infant, Adolescence, Nursing, Birth control, Toy, Psychology, Neuroscience, Psychotherapy, Child, Psychiatry, Research

To address this pressing concern and mobilise global efforts, the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), International Society for Adolescent Psychiatry and Psychology (ISAPP), World Association for Infant Mental Health (WAIMH), and World Psychiatric Association Child and Adolescent Psychiatry (WPA-CAP) have jointly declared April 23 as the World Infant, Child and Adolescent Mental Health Day (WICAMHD).

Key Points: 
  • To address this pressing concern and mobilise global efforts, the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), International Society for Adolescent Psychiatry and Psychology (ISAPP), World Association for Infant Mental Health (WAIMH), and World Psychiatric Association Child and Adolescent Psychiatry (WPA-CAP) have jointly declared April 23 as the World Infant, Child and Adolescent Mental Health Day (WICAMHD).
  • This year witnessed the second annual WICAMHD event under the theme of Stand Against Infant, Child and Adolescent Trauma.
  • Dr Dennis Ougrin, Consultant Child and Adolescent Psychiatrist, Visiting Professor of Child and Adolescent Psychiatry and Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, King's College London discussed the impacts of the war in Ukraine.
  • These include the Indian Association for Child and Adolescent Mental Health (IACAM), the Lithuanian Society of Child and Adolescent Psychiatry (LVPPD), the American Academy of Child and Adolescent Psychiatry (AACAP), the Austrian Society of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (ASCAP) and the Section of Child and Adolescent Psychiatry, College of Psychiatrists, Academy of Medicine, Singapore (SCAP).

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Retrieved on: 
Wednesday, May 31, 2023
Macrophage, ISCT, Immunotherapy, ID, CELL, Cell, AN, Poster, Therapy, International Society, Vaccine

Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced three poster presentations, including a selected Elevator Pitch Presentation at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy (ISCT), which is taking place from May 31, 2023 through June 03, 2023 in Paris, France.

Key Points: 
  • Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced three poster presentations, including a selected Elevator Pitch Presentation at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy (ISCT), which is taking place from May 31, 2023 through June 03, 2023 in Paris, France.
  • The poster (ID#805) presentation, “DEVELOPMENT OF A FROZEN FORMULATION OF ALLOCETRA-OTS, AN INNOVATIVE MACROPHAGE REPROGRAMMING CELL-BASED THERAPY”, which details the development and regulatory acceptance of Allocetra frozen formulation, was selected for presentation at the Elevator Pitch Session on Wednesday, May 31, 2023 from 7:00 PM to 8:00 PM CEST, session room 241.
  • The second poster (ID#1003) presentation, “IN VITRO BIOLOGICAL ACTIVITY CHARACTERIZATION AND CELL BASED POTENCY ASSAY DEVELOPMENT FOR ALLOCETRA OTS”, will take place on June 1, 2023 from 6:00 PM to 7:30 PM CEST.
  • The third poster (ID#1057) presentation, “SYNERGISTIC PERITONEAL ANT-TUMOR EFFECT OF ALLOCETRA-OTS, A CELLULAR IMMUNE THERAPY , IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS/CHEMOTHERAPY THROUGH REPROGRAMMING OF MACROPHAGES AND DENDRITIC CELLS”, will take place on June 1, 2023 from 6:00 PM to 7:30 PM CEST.